Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer

  * Stage IB (T2, N0), II (T1 or T2, N1 or T3, N0), or IIIA (T3, N1)
  * Potentially resectable disease
* No large central primary tumors in proximity to significant blood vessels
* No bronchoscopically evident endobronchial tumors
* At least 1 unidimensionally measurable lesion

  * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
* No known brain metastases

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* ECOG 0-1 OR
* Karnofsky 70-100%

Life expectancy:

* More than 12 months

Hematopoietic:

* WBC at least 3,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* No history of an inherited bleeding disorder
* No inherited predisposition to a hypercoagulable state
* No clinically evident hypercoagulable state or bleeding diathesis

Hepatic:

* Bilirubin less than 1.5 times upper limit of normal (ULN)
* AST/ALT no greater than 2.5 times ULN
* INR less than 1.5
* PTT less than 36 seconds

Renal:

* Creatinine less than 1.5 times ULN OR
* Creatinine clearance at least 60 mL/min
* No nephrotic syndrome
* Urine protein no greater than 0.5 g/24 hours

Cardiovascular:

* No poorly controlled hypertension (greater than 150 mm Hg systolic and/or greater than 100 mm Hg diastolic) despite treatment
* No uncompensated coronary artery disease
* No myocardial infarction within the past 6 months
* No clinically significant or severe peripheral vascular disease
* No inherited predisposition to thrombosis
* No deep venous or arterial thrombosis
* No symptomatic congestive heart failure
* No unstable angina pectoris within the past 6 months
* No cardiac arrhythmia
* No transient ischemic attack within the past 6 months
* No cerebrovascular accident within the past 6 months
* No other arterial thromboembolic event within the past 6 months

Pulmonary:

* No hemoptysis
* No pulmonary embolism

Other:

* No history of allergic reactions to compounds of similar chemical or biologic composition to study drugs
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No psychiatric illness or social situation that would preclude study compliance
* No significant traumatic injury within the past 28 days
* No uncontrolled concurrent illness
* No ongoing or active infection
* No serious, non-healing wound, ulcer, or bone fracture
* No other active malignancy
* No requirement for full-dose anticoagulation or thrombolytic therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior biologic therapy for this cancer
* No concurrent prophylactic growth factors (e.g., epoetin alfa, filgrastim \[G-CSF\], or sargramostim \[GM-CSF\])

Chemotherapy:

* No prior chemotherapy for this cancer
* Prior chemotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled

Endocrine therapy:

* No prior endocrine therapy for this cancer

Radiotherapy:

* No prior radiotherapy for this cancer
* Prior radiotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled
* No concurrent radiotherapy

Surgery:

* Prior diagnostic bronchoscopy, mediastinoscopy, or CT-guided biopsy allowed
* At least 28 days since prior major surgical procedure or open biopsy

Other:

* No other concurrent investigational agents
* No other concurrent anticancer investigational or commercial agents or therapies
* No concurrent combination antiretroviral therapy for HIV-positive patients
* Concurrent low-dose warfarin for maintenence of preexisting, permanent, indwelling IV catheters allowed provided INR less than 1.5